Antigen Discovery

Antigen Discovery Inc. operates as a specialized research services and products company, leveraging its proprietary proteome microarray technology to enable rapid, proteome-wide screening for antibody and T-cell responses. Its core business model is providing customized solutions and collaborative services to partners in infectious disease and vaccine development, significantly reducing the traditional timeline for antigen discovery from years to weeks. The company has built an extensive library of expressible open reading frames from over 50 pathogens and collaborates with leading institutions like the NIH and University of Washington. While primarily a service provider, its technology platform has direct applications in identifying diagnostic biomarkers and vaccine candidates for its partners' pipelines.

High-throughput proteome microarray technology for translating genomes into printed protein arrays, enabling rapid, proteome-wide screening for antibody binding and T cell reactivity. Includes a proprietary process for ORF library construction, cell-free protein expression, microarray printing, and bioinformatic analysis.

ADI competes with other companies offering high-throughput protein screening and display technologies (e.g., phage display, yeast display), as well as academic core facilities and large life science tools companies providing proteomic analysis services. Its differentiation lies in its turn-key, proteome-wide approach, extensive pre-built pathogen libraries, and integrated T cell screening capability.